Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: Lessons learned from vitiligo

Modern Pathology

Volumn 19, Issue 9, 2006, Pages 1255-1260

  Singh, Zeba N ^a   Tretiakova, Maria S ^a   Shea, Christopher R ^a   Petronic Rosic, Vesna M ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

CD117; Hypopigmented mycosis fungoides; KIT; Melanosomal antigens; Pathogenesis; Vitiligo

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A; MONOPHENOL MONOOXYGENASE; STEM CELL FACTOR RECEPTOR;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN TISSUE; HYPOMELANOSIS; HYPOPIGMENTATION; HYPOPIGMENTED MYCOSIS FUNGOIDES; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MELANOCYTE; MELANOMA; MELANOSOME; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN BIOPSY; T LYMPHOCYTE; VITILIGO;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; MELANOCYTES; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; MYCOSIS FUNGOIDES; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VITILIGO;

EID: 33747593269     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800644     Document Type: Article

References (29)

1. Ardigo M, Borroni G, Muscardin L, et al. Hypopigmented mycosis fungoides in Caucasian patients: a clinicopathologic study of 7 cases. J Am Acad Dermatol 2003;49:264-270.
2. Capizzi R, Rotoli M, Cavalieri S, et al. Hypopigmented mycosis fungoides in a 12-year-old caucasian girl with solely hypopigmented lesions. Dermatology 2003;207:201-202.
3. Neuhaus IM, Ramos-Caro FA, Hassanein AM. Hypopigmented mycosis fungoides in childhood and adolescence. Pediatr Dermatol 2000;17:403-406.
4. Whitmore SE, Simmons-O'Brien E, Rotter FS. Hypopigmented mycosis fungoides. Arch Dermatol 1994;130:476-480.
5. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
6. Ben-Amitai D, Michael D, Feinmesser M, et al. Juvenile mycosis fungoides diagnosed before 18 years of age. Acta Derm Venerol 2003;83:451-456.
7. El-Shabrawi-Caelen L, Cerroni L, Medeiros LJ, et al. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am J Surg Pathol 2002;26:450-457.
8. Wain EM, Orchard GE, Whittaker SJ, et al. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer 2003;98:2282-2290.
9. Peters MS, Thibodeau SN, White Jr JW, et al. Mycosis fungoides in children and adolescents. J Am Acad Dermatol 1990;22:1011-1018.
10. Breathnach SM, McKee PH, Smith NP. Hypopigmented mycosis fungoides: report of five cases with ultrastructural observations. Br J Dermatol 1982;106:643-649.
11. Goldberg DJ, Schinella RS, Kechijian P. Hypopigmented mycosis fungoides. Speculations about the mechanism of hypopigmentation. Am J Dermatopathol 1986;8:326-330.
12. Bouloc A, Grange F, Delfau-Larue MH, et al. Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases. The French Study Group of Cutaneous Lymphomas. Br J Dermatol 2000;143:832-836.
13. Steitz J, Wenzel J, Gaffal E, et al. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol 2004;83:797-803.
14. Mandelcorn-Monson RL, Shear NH, Yau E, et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003;121:550-556.
15. van Den Wijngaard R, Wankowicz-Kalinska A, Pals S, et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001;81:1061-1067.
16. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003;16:90-100.
17. Gauthier Y, Andre MC, Taieb A. A critical appraisal of vitiligo etiologic theories: is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-332.
18. Grimes PE, Sevall JS, Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 1996;35:21-26.
19. Kitamura R, Tsukamoto K, Harada K, et al. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 2004;202:463-475.
20. Lee AY, Kim NH, Choi WI, et al. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J Invest Dermatol 2005;124:976-983.
21. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. Nature 1998;391:298-301.
22. Tachibana M, Takeda K, Nobukuni Y, et al. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Nat Genet 1996;14:50-54.
23. Hou L, Panthier JJ, Arnheiter H. Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development 2000;127:5379-5389.
24. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-718.
25. Palermo B, Campanelli R, Garbelli S, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001;117:326-332.
26. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208.
27. Becker JC, Guldberg P, Zeuthen J, et al. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999;113:1033-1038.
28. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell-mediated vitiligo. J Exp Med 2000;192:1637-1644.
29. El-Darouti MA, Marzouk SA, Azzam O, et al. Vitiligo vs hypopigmented mycosis fungoides (histopathological and immunohistochemical study, univariate analysis). Eur J Dermatol 2006;16:17-22.